Alchemab is a biotechnology company that develops antibody therapeutics. The company focuses on advancing novel antibodies with potential applications in various diseases, including Parkinson's disease.

Alchemab

Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of hard-to-treat disease in a unique and transformative approach to drug discovery and development. 
Alchemab takes an unbiased and function-first approach using three complementary processes and cutting-edge technologies to identify naturally protective antibodies.
Alchemab’s engine is enabled through collaborations with patient representative groups and biobanks around the world with whom we partner to further our understanding of disease.

Michael J. Fox Foundation

Biomedical Catalyst Fund

DCVC Bio

Dementia Discovery Fund

Lightstone Ventures

RA Capital Management

SV Health Investors

DHVC

DCVC

Alchemab Therapeutics Ltd

Principal Scientist at #Alchemab, Helen Graves, is presenting at the One Nucleus Innovation Seminar in Cambridge on the 'Challenges and Opportunities in Therapeutic Antibody Development'! Don't miss Helen's presentation on 5 September at 16:40pm BST, titled 'Antibodies From Resilient Individuals: A Novel Approach for Antibody Drug Discovery'.
 
Sign up to attend if you haven't already!
 
#biotech #lifesciences #antibodies #neuroscience

#Alchemab is proud to highlight that 15 team members will be taking part in the 3 Peaks Walk in Derbyshire to fundraise for our charity of the year, Age UK!
 
 The team will be heading to Derbyshire to complete 20 miles of hiking across the three highest points in the Peak District National Park on 21st September.
 
We wish them the best of luck on their walk as they continue to fundraise vital funds towards supporting Age UK in Cambridgeshire & Peterborough, who provide various services for older people and their carers.
 
 If you would like to donate to enable #AgeUK to continue their incredible work, please use the link here! https://lnkd.in/gJ4if8Vy

Thank you to everyone who has already donated for this important cause and good luck to the team!
 
#biotech #lifesciences #Cambridgeshire #Peterborough

In case you missed it, #Alchemab was featured in Drug Discovery World’s insightful report: 'Neuroscience: Advances in research and opportunities ahead', highlighting our 'patient-centric approach'! 💡

📰 Download the free report to read more about our unique approach to #drugdiscovery and our program, ATLX-1088, a CD33 inhibitor which 'offers a promising and novel therapeutic approach for the treatment of Alzheimer's disease'.

https://lnkd.in/eCEEdBCu

#biotech #lifesciences #antibodies #neuroscience #alzheimers

Alchemab is supporting The Boston Home as its US charity partner for 2024. Find out more about how Alchemab contributes to this charity's important work to support healthy aging in the article below.  
#healthyaging  #neurology #partnershipsmatter

Alchemab staff are proud to volunteer their time, raising money and awareness for charities aligned with our values and scientific focus. Today we announced that we have selected Age UK Cambridgeshire and Peterborough as our UK Charity for 2024. Read on to learn why we look forward to working with Age UK.

Alchemab Therapeutics Ltd are delighted to share that its paper titled 'A generative foundation model for antibody sequence understanding' has been accepted for two workshops at the 41st [ICML] Int'l Conference on Machine Learning in Vienna, Austria.
 
This paper introduces FAbCon, a generative antibody-specific language model comprising 2.4 billion parameters and will be presented as a poster at the workshops on Machine Learning for Life and Material Science (ML4LMS) on July 26th, and Accessible and Efficient Foundation Models for Biological Discovery (AccML) on July 27th.
 
To read our paper or download our models, use the links in the comments below!

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Sep 4, 2024 5:58 AM	e23d83d5
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Sep 4, 2024 10:36 AM	2dd4356f
company summary	general
signals	general
crunchbase trigger	general	Nov 27, 2024 12:50 PM	f6653053
crunchbase profile	general
li profile	general	Sep 4, 2024 5:58 AM	c6362d97
translate crunchbase fundingrounds	general
peers	general	Sep 4, 2024 5:58 AM	3479c585
news basic	general	Sep 4, 2024 5:58 AM	68d1f845
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:ALCHEMAB

Alchemab